Johnson & Johnson
JNJ • NYSE
Johnson & Johnson is a drug manufacturers - general company in the healthcare sector trading on NYSE, led by CEO Joaquin Duato, with a market cap of $584.38B.
CEOJoaquin Duato
Market Cap$584.38B
Drug Manufacturers - General
Healthcare
Employees134.4K
Websitejnj.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Johnson & Johnson
Date
Tuesday, April 14, 2026 (in 2 months)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$2.69
Revenue Estimate
$23.5B
Earnings History
Past 12 earnings reports for Johnson & Johnson
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Jan 21, 2026 | Q4 2025 | $2.46Est: $2.47 | -0.4% | $24.6BEst: $24.2B | +1.7% | — |
| Oct 14, 2025 | Q3 2025 | $2.80Est: $2.76 | +1.4% | $24.0BEst: $23.7B | +1.0% |  10-Q |
| Jul 16, 2025 | Q2 2025 | $2.77Est: $2.67 | +3.7% | $23.7BEst: $22.8B | +4.0% | 10-Q |
| Apr 15, 2025 | Q1 2025 | $2.77Est: $2.60 | +6.5% | $21.9BEst: $21.6B | +1.5% | 10-Q |
| Jan 22, 2025 | Q4 2024 | $2.04Est: $2.02 | +1.0% | $22.5BEst: $22.5B | +0.3% | 10-K |
| Oct 15, 2024 | Q3 2024 | $2.42Est: $2.21 | +9.5% | $22.5BEst: $22.2B | +1.4% | 10-Q |
| Jul 17, 2024 | Q2 2024 | $2.82Est: $2.70 | +4.4% | $22.4BEst: $22.3B | +0.6% | 10-Q |
| Apr 16, 2024 | Q1 2024 | $2.71Est: $2.64 | +2.7% | $21.4BEst: $21.4B | -0.1% | 10-Q |
| Jan 23, 2024 | Q4 2023 | $2.29Est: $2.28 | +0.4% | $21.4BEst: $21.0B | +1.9% | 10-K |
| Oct 17, 2023 | Q3 2023 | $2.66Est: $2.51 | +6.0% | $21.4BEst: $21.0B | +1.5% | 10-Q |
| Jul 20, 2023 | Q2 2023 | $2.80Est: $2.62 | +6.9% | $25.5BEst: $24.6B | +3.7% | 10-Q |
| Apr 18, 2023 | Q1 2023 | $2.68Est: $2.51 | +6.8% | $24.7BEst: $23.7B | +4.5% | — |